NasdaqGM - Nasdaq Real Time Price USD
CRISPR Therapeutics AG (CRSP)
53.72 -0.27 (-0.50%)
As of 2:58:34 PM EDT. Market Open.
Trade CRSP on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for CRSP
- Previous Close
53.99 - Open
54.15 - Bid 53.10 x 100
- Ask 69.33 x 200
- Day's Range
53.63 - 55.48 - 52 Week Range
44.12 - 78.48 - Volume
897,356 - Avg. Volume
1,686,527 - Market Cap (intraday)
5.291B - Beta (5Y Monthly) 1.70
- PE Ratio (TTM)
-- - EPS (TTM)
-6.17 - Earnings Date (est.) May 11, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
83.52
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
CRSP
2.44%
S&P 500 (^GSPC)
7.32%
1-Year Return
CRSP
14.84%
S&P 500 (^GSPC)
20.59%
3-Year Return
CRSP
4.12%
S&P 500 (^GSPC)
68.95%
5-Year Return
CRSP
61.04%
S&P 500 (^GSPC)
72.19%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
5.32B
Enterprise Value
3.66B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.99k
Price/Book (mrq)
2.93
Enterprise Value/Revenue
3.66k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.06%
Return on Equity (ttm)
-31.21%
Revenue (ttm)
4.1M
Net Income Avi to Common (ttm)
-568.53M
Diluted EPS (ttm)
-6.17
Balance Sheet and Cash Flow
Total Cash (mrq)
2.44B
Total Debt/Equity (mrq)
43.41%
Levered Free Cash Flow (ttm)
-260.9M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreCrispr Earnings: Casgevy Progress Helps Derisk Platform; Early-Stage Pipeline Assets Make Progress
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
RatingPrice TargetCrispr Earnings: Casgevy Progress Helps Derisk Platform; Early-Stage Pipeline Assets Make Progress
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
RatingPrice TargetCrispr Earnings: Casgevy Progress Helps Derisk Platform; Early-Stage Pipeline Assets Make Progress
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
RatingPrice TargetPositive Long-Term Outlook for Crispr Therapeutics as Gene Editing Portfolio Makes Progress
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
RatingPrice Target